---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000002"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:05:37.426445+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere reports ~$74M preliminary Q4 net product sales; FILSPARI PSFs up 40% QoQ

## Summary
- Preliminary Q4 2024 FILSPARI net sales ~$50M; total Q4 net product sales ~$74M; FY2024 ~$227M.
- Received 693 new FILSPARI patient start forms in Q4, a 40% sequential increase in net sales vs Q3.
- Cash, equivalents and marketable securities ~$371M at year-end 2024.
- FDA accepted sNDA to modify liver monitoring for FILSPARI in IgAN; PDUFA date Aug 28, 2025.
- On track for FSGS regulatory pathway update by Q4 2024 earnings call; partner CSL Vifor milestone $17.5M upon European full approval.

## SEC filing metadata
- accession: 0001438533-25-000002
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/0001438533-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/tvtx-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000002
- JSON: https://secwatch.observer/filing/0001438533-25-000002.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.